Cardiac Power Output in Cardiogenic Shock Patients

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Dobutamine; Milrinone

Criteria

Inclusion Criteria:

1. LVEF ≤ 35%

2. Referred for RHC for:

1. Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR

2. Accurate assessment of invasive hemodynamics due to worsening clinical status, OR

3. Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR

4. Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI

3. Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2

4. Age ≥ 18 years-old

5. Intent for admission based on RHC data

Exclusion Criteria:

1. eGFR < 30 ml/min/1.73 m2

2. Severe, non-revascularized coronary artery disease

3. Concurrent acute coronary syndrome

4. Age < 18 years-old

5. History of significant ventricular arrhythmia without an ICD